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ABSTRACT (Word-count 192) 
Non-erosive reflux disease (NERD) is a common condition and the most frequent phenotype 
of GERD. NERD is extremely heterogeneous and includes patients with negative endoscopy, but 
abnormal esophageal acid exposure and/or positive reflux-symptom association analysis 
(hypersensitive esophagus). This segregation is only possible thanks to the use of impedance-pH 
monitoring. Indeed, weakly acidic reflux represents one of the most frequent cause of refractory 
symptoms in patients evaluated off-anti-secretory therapy and, more importantly, during anti-
secretory drug treatment. Patients with heartburn who do not have any type of reflux underlying 
their symptoms (functional heartburn) must be excluded from the category of GERD. The 
drawbacks of impedance-pH are mainly due to the day-to-day variability of the test and by the fact 
that the accuracy of the symptom-reflux correlation scores are often far from being perfect. Some 
histopathological characteristics, as dilated intercellular spaces, can be helpful to distinguish 
patients with NERD by esophageal biopsies. As to the outcome, patients with NERD in whom acid 
is the main pathogenetic factor respond successfully to PPI therapy, while those with hypersensitive 
esophagus to weakly acidic reflux could be treated with reflux inhibitors or surgery, although 
further controlled studies are required. 
 
  
Definition of NERD and sub-groups 
Heartburn, or retrosternal burning, is a typical symptom of gastroesophageal reflux disease 
(GERD) that frequently affects a large part of population (10%-20%) in Western countries, 
interfering significantly with the quality of life of many patients.
1
  
For many years, erosive reflux disease has been considered the more common manifestation 
of GERD, nevertheless, in the past decade it has been realized that erosive reflux disease represents 
the minority of patients with GERD (~30%), whereas the majority of them (~70%) are included in 
the non-erosive reflux disease (NERD) phenotype, characterized by the presence of typical reflux 
symptoms without any esophageal mucosal lesion visible at endoscopy.
2, 3
 
Pathophysiological studies carried out with 24-hour esophageal multichannel intraluminal 
impedance–pH testing (MII-pH) have demonstrated that patients with NERD phenotype are 
markedly heterogeneous and can be subdivided into several well-defined subgroups. Currently, the 
NERD definition includes patients with negative endoscopy but abnormal esophageal acid exposure 
(AET).3-6 Further, in the NERD population, we can include patients with negative endoscopy and 
normal pathophysiological testing (pH-metry/MII-pH), both for AET and total number of reflux 
events, but with these latter variables temporarily correlated with symptoms (Hypersensitive 
esophagus, HE).6 The correlation between symptoms and reflux events is commonly defined by 
means of symptom index (SI positive if > 50%) and symptom association probability (SAP, positive 
if > 95%).6 Patients may be hypersensitive to both acid and/or non-acid reflux events.4, 7, 8 Patients 
with heartburn refractory to proton pump inhibitors (PPIs), who show negative endoscopy, normal 
AET and number of refluxes and no correlation between symptoms and reflux, should be 
considered as patients with functional heartburn (FH)4, 6, 9 and should not be considered and treated 
as GERD patients (i.e. stopping any kind of anti-secretory therapy and not undergoing anti-reflux 
surgery). The most universal definition of FH was indicated by the Rome III experts in 2006, who 
suggested that these patients present chronic retrosternal burning in the absence of either GERD 
(detected by pH-metry) or histopathology-based esophageal motility disorders.
10
 Thereafter, 
Savarino et al.
9
 demonstrated the added value of MII-pH in distinguishing patients with GERD 
from those affected by FH, by showing a 10% diagnostic gain with this technique. Similar results 
were obtained in following studies performed both “off PPI therapy”7, 11-14 (10-15% diagnostic gain) 
and “on PPI therapy”11, 12, 15, 16 (20-40% diagnostic gain) with MII-pH testing. Overall, the added 
values and the clinical application of impedance monitoring should help the clinicians to correlate 
an increased number of symptoms with reflux events, thus increasing the number of patients with 
reflux disease and reducing the rate of patients with FH.  
 
Clinical characteristics 
The positive or negative response of patients with heartburn to PPI therapy is an empiric 
criterion, which can include or exclude from the definition of GERD those patients who complain 
of heartburn and do not have an objective demonstration of the presence or absence of gastro-
esophageal reflux. However, it has been estimated that 25%-40% of patients complaining of 
heartburn continue to present symptoms despite daily PPI use and that there is a large group of 
patients with functional disorders rather than GERD who may respond to PPI due to a placebo 
effect.
5, 17
 Previous studies have underlined this important limitation, which affects the diagnostic 
accuracy of the PPI test.
18, 19
 In particular, Bytzer et al.
20
 carried out a study in a sample of well-
defined primary care patients with suspected GERD, and demonstrated the limited ability of a PPI 
trial to identify patients with GERD, using endoscopy, esophageal pH-metry and reflux disease 
questionnaires as reference standard. Presence or absence of gastro-esophageal reflux during barium 
esophagography does not correlate with incidence or extent of reflux observed during MII-pH 
monitoring and it is not of value for the diagnosis of GERD.
19, 21
  
A symptom based approach using a questionnaire (GERDQ) does not always confirm 
GERD diagnosis.
22, 23
 Multiple studies have demonstrated that patients with objective evidence of 
reflux tend to be older, male, and smokers in comparison to patients with FH.
24-27
 Increased body 
mass index (>25 kg/m
2
) is also associated with PPI failure in patients with acid reflux compared 
with those patients with HE or FH.
27-29
 Further, there are different evidences suggesting a strong 
association between FH and other functional disorders such as functional dyspepsia and/or irritable 
bowel syndrome, emphasizing the hypothesis of a unique “whole gut” GI disorder.30-32  
However, currently, demographics do not reliably distinguish subgroups of patients 
suffering from heartburn.
25, 33
 Understanding the epidemiology and pathogenesis of patients with 
FH may allow early recognition of these patients and could help to anticipate and avert therapeutic 
failure.
34
 
 
MII-pH diagnosis and different GERD phenotypes 
Patients often undergo extensive functional testing to evaluate heartburn if there is 
inadequate response to optimal acid suppressive therapy, as this approach seems to be useful in 
differentiating FH from refractory acid reflux. To note, optimal acid therapy is not well-defined in 
the literature. In the setting of objective acid testing, an effective therapy may be considered the 
adequate control of acid assessed by a functional examination. However, a simple and more often 
used definition for optimal acid suppression is the lack of symptoms in response to acid suppression 
(defined as twice a day proton pump inhibition).
6, 35
 
The complete chemical nature of reflux can be detected neither by traditional esophageal 
pH-metry nor by the catheter-free Bravo™ system,36 but the advent of 24 h MII-pH testing has 
enabled differentiation of acid from weakly acidic reflux or nonacid reflux (that is weakly acidic 
reflux and weakly alkaline reflux).
37
 Indeed, reflux of gastric content into the esophagus is a 
physical event that has been evaluated for long time only by means of techniques able to obtain 
information on the chemical component of refluxate. The MII-pH was an innovative technique that 
provided a detailed characterization of each reflux event including chemical (acid and non-acid 
reflux) and physical properties (liquid, mixed, gas).
37, 38
 In the last decade, it has been shown that 
nonacid reflux represents the majority of reflux episodes in patients with GERD on PPI therapy.
39, 40
 
Indeed, the total number of reflux episodes is not affected by acid suppressive therapy, and weakly 
acidic reflux accounts for approximately 90% of all reflux episodes in patients on PPIs, thus 
representing a potential mechanism underlying the failure of PPI treatment in patients with reflux-
related symptoms.
12, 15
 Further, the assessment of both acid and non-acid reflux correlation with 
symptoms may allow us to better select patients who would benefit from anti-reflux surgery or an 
endoscopic anti-reflux procedure.
41
 
However, all of the available tests for GERD diagnosis have some limitations. The 
drawbacks of MII-pH are mainly due to the day-to-day variability of the test.
42-44
 Additionally, the 
reflux-symptom correlation in patients with GERD who do not respond to PPI therapy is actually  
calculated by the symptom index (SI) or symptom association probability (SAP), although their 
validity is still uncertain.
45, 46
 Unfortunately, symptoms may not occur during 24-hour reflux 
monitoring. Moreover, the attention of patients in symptom recording is often far from perfect. As a 
consequence, SAP/SI may be negative even in several patients with erosive reflux disease (ERD), 
as we found in several series. Therefore, in pH-negative patients a positive SAP/SI indicates reflux-
related heartburn,
4, 47
 but a negative SAP/SI does not exclude GERD; indeed, patients with 
heartburn may respond to PPI therapy despite normal MII-pH findings.
48
 Accordingly, Zerbib et 
al.
49
 reported that MII-pH results were not always able to predict the response to PPIs in patients 
with typical reflux-related symptoms, when the test was performed off PPI therapy.
50
  
Recently, the ability of MII-pH testing in better understanding GERD pathophysiology has 
improved by means of new parameters, such as the post-reflux swallow-induced peristaltic wave 
(PSPW ) index, which indicates the efficacy of esophageal clearance,
51
 and the baseline impedance 
values, which indicate the presence of a lack of integrity in the esophageal mucosa.
52
 PSPW index 
has been shown to be lower in patients with abnormal AET, compared to healthy volunteers (HVs) 
or FH.
51
 Moreover, this parameter was not altered after medical or surgical therapy.
53
 Further, 
Kessing et al.
53
 described lower values of baseline impedance levels in the distal esophagus of 
patients with abnormal esophageal AET, compared to HVs. Recently, many studies standardized 
the measurement of baseline impedance by calculating the mean nocturnal baseline impedance 
(MNBI) across three 10-min periods between 1 AM and 3 AM, away from daytime esophageal 
physiologic activity.
48, 54, 55
 The most relevant advantages regarding both the MBNI and PSPW 
index have been recently published by Frazzoni et al.
55
 The authors showed a gradient behaviour of 
them across 289 GERD patients and 50 healthy controls, being both parameters worse in erosive 
esophagitis compared with NERD and healthy controls. The diagnostic yield of both parameters 
was greater than that of increased AET, total reflux events, and bolus exposure time in both erosive 
esophagitis and NERD. Furthermore, MNBI and PSPW index make pathophysiologic sense, and 
certainly deserve a chance in redeeming the clinical value of ambulatory MII-pH testing.
56
  
There are still others information that could be caught from a more in deep analysis of MII-pH 
tracing such as the role of bolus contact time in improving GERD diagnosis
57
 or gas and mixed 
reflux or supragastric belching in increasing symptom perception.
58, 59
  
 
Weakly acidic reflux and refractory heartburn 
The Porto consensus report provided a detailed nomenclature for reflux patterns detected by 
MII- pH monitoring.
37
 An impedance detected reflux is defined as acid when the esophageal pH 
falls to < 4, or when reflux occurs with the esophageal pH already < 4. When the esophageal pH 
falls by ≥ 1 unit, but remains > 4, it is considered “weakly acidic reflux.” 
The prevalence of weakly acidic reflux (WARs) in refractory GERD depends on the way 
reflux monitoring is performed. Although several WAR episodes can be detected during 24-hour 
MII-pH monitoring “off” PPI, this type of refluxate becomes particularly significant during studies 
“on” PPI.12, 15, 60, 61 Vela et al.61 used stationary MII-pH monitoring to compare postprandial 
recordings of the same subject “on” and “off” PPI. The antisecretory treatment provoked no 
reduction in the total number of reflux events, but there was a shift in the refluxate’s pH from acidic 
to weakly acidic. Heartburn was replaced by regurgitation, which became the predominant 
symptom in these patients. Studies in patients with refractory GERD showed that WARs could be 
associated with 30%-40% of symptoms.
12, 15
 In another study Zerbib et al.
62
 observed that in a 
group of patients with refractory heartburn WARs were associated to both heartburn and 
regurgitation in patients evaluated on double dose PPI therapy. The role of WARs in patients with 
typical refractory symptoms has been studied, almost always, in patients on PPIs. Few but 
intriguing data have been reported on WARs evaluated in patients off-therapy and it was confirmed 
that this type of chemical reflux can be associated with both heartburn and regurgitation.
63-65
  
The mechanisms by which WAR can provoke persistence of symptoms remain 
controversial, as several factors have been proposed: (1) esophageal distension by increased reflux 
volume 
62
, (2) persistent impairment of esophageal mucosa due to weakly acidic reflux containing 
bile acids
66
 and (3) esophageal hypersensitivity to non-acid components of gastric contents either 
when gas is present in the refluxate
67
 or after esophageal sensitization due to an acid reflux.
68
 
Accordingly, Rohof et al.
69
 showed that PPI-resistant symptoms are most likely explained by 
increased proximal reflux in a hypersensitive esophagus and less likely by increased mucosal 
permeability or by the position of the acid pocket.  
By the way, there is no doubt that WAR can be one of the underlying mechanisms of 
refractory GERD. In order to establish definitely its role, prospective studies comparing the impact 
of WAR in patients with PPI failure and with PPI success are needed and, even more importantly, 
we are still waiting for positive controlled outcome studies targeting this type of reflux. 
 
Histopathology changes and mucosal barrier integrity in NERD subgroups 
The integrity of the mucosal epithelial barrier is of great importance to prevent pathologic 
consequences of reflux, and can be overcome in the disease state (whether erosive or non-erosive). 
So, it is of relevance to discuss the structures responsible for maintenance of mucosal integrity. 
The pre-epithelial defense consists of a small water layer with limited buffering capacity, 
presumably due to the presence of bicarbonate derived from swallowed salivary fluid and from 
secretions of esophageal submucosal glands.
70
 In patients with esophagitis there is a clear breach in 
this barrier allowing components of the refluxate to reach the nociceptors in the lamina propria.
70
 
Acid and acid-pepsin initially attack and damage the intercellular junctions, thus resulting in an 
increase in para-cellular permeability, reflected morphologically by the presence of dilated 
intercellular spaces.
71
  
From a diagnostic point of view, esophageal biopsies might be helpful to identify patients 
with histological signs of GERD. Further, it is relevant to underline that the addition of esophageal 
biopsies as an adjunct to an endoscopic examination has been re-emphasized because of the 
progressively increased prevalence of eosinophilic esophagitis (EoE). Many clinicians routinely 
take esophageal biopsies  in patients with reflux-type symptoms to search for EoE in the setting of 
an endoscopy that does not reveal erosive changes.
72
  
Histological examination of esophageal biopsies may help in distinguishing patients with 
NERD from FH, as dilated intercellular spaces can be a microscopic marker of reflux and 
esophageal damage frequently associated with NERD and only rarely with FH.
73
 The presence of 
dilated intercellular spaces may also predict a non-response to acid suppression.
74
 Using light 
microscopy (LM), it is possible to combine multiple histological alterations denoting the presence 
of microscopic esophagitis (ME), such as basal cell hyperplasia, papillae elongation, and DIS.
75-77
 
Zentilin et al.
76
 proposed a histological score able to discriminate between GERD and controls with 
a positive predictive value of 97% and a negative predictive value of 46%. 
It has been also hypothesized that there is a good correlation between DIS in the esophageal 
epithelium of both ERD and NERD patients and the presence of heartburn.
78
 Recently, Savarino et 
al.
79
 demonstrated the lack of microscopic esophagitis (ME) in the esophageal distal biopsies of FH 
patients, suggesting a limited role of these histological abnormalities in symptom generation in 
them. ME can be considered as an accurate and reliable diagnostic marker for distinguishing FH 
patients from GERD patients and has the potential to be used to guide the correct therapy. 
Fiocca et al.
80
 developed consensus guidelines for histologic recognition of ME in patients 
with GERD and proposed several criteria, which achieved high levels of agreement when assessed 
independently by 5 pathologists.  
Recently, Kandulsky et al.
81
 confirmed that esophageal biopsies are useful to differentiate 
NERD from FH, especially in patient with refractory heartburn. The same authors showed that low 
levels of baseline impedance (detected with 24-h MII-pH) are associated with increased exposure to 
acid and dilation of intercellular spaces, indicating a strong correlation between esophageal mucosal 
impairment and baseline impedance.
82
 
However, these histological alterations are not still adequately sensitive and specific to be 
used in a diagnostic algorithm, and so far routine esophageal biopsies as a means of making a sound 
diagnosis of FH are not recommended.  
 
Aerophagia, gas reflux and supragastric belching in pathophysiology of NERD 
Aerophagia is a condition of excessive air swallowing, which goes to the stomach. 
Pouderoux et al.
83
 observed, by means of ultrafast computerized tomography, a substantial 
aerophagia (8-32mL of air) during transit of a swallowed bolus through the esophagus and a partial 
bolus separation with air preceding fluid. Bravi et al.
84
 demonstrated that PPI non-responder 
patients with GERD swallowed more air at mealtime than those who respond to PPI treatment and 
also have more reflux episodes that contain gas. The authors concluded that air swallow combined 
with mucosal sensitization could affect perception of symptoms.  
Gastric belching (frequent gas-reflux events during MII-pH 24-h) is the escape of swallowed 
intragastric air that enters the esophagus during a transient lower-esophageal sphincter relaxation 
(TLESR).
85
 Gastric belches occur 25 to 30 times per day and are physiological, involuntary and 
controlled entirely by reflexes. Belching does not seem to facilitate acid reflux in heathy subject.
86
 
On the other hand, the presence of gas into the refluxate  enhances reflux perception,  is frequently 
associated with proximal extent of reflux and occurs more frequently in patients who do not 
respond to acid suppressive treatment.
63, 67, 84, 87
  
In supragastric belches the air does not originate from the stomach but is ingested 
immediately before it is expelled again.
88
 Supragastric belches are not a reflex but, instead, are the 
result of human behavior. Studies with simultaneous impedance monitoring and high-resolution 
manometry reveal the underlying mechanism of this behavior: a contraction of the diaphragm 
creates a negative pressure in the thoracic cavity and the esophagus, subsequent relaxation of the 
UES, resulting in inflow of air into the esophagus.
89
 It is unclear what causes supragastric belching 
and what causes patients to start this behavior. Some patients report that initially they belched 
purposefully to relieve a sensation of bloating or abdominal discomfort but that with time they lost 
control of the belching.
88
 Many patients stop belching during speaking and sleeping; it has been 
shown that distraction also reduces the frequency of belching, whereas putting attention to their 
belching behavior usually results in an increase in belching frequency.
90
 Recently Koukias et al.
59
 
described 100/2950 patients, over a 4 years period, with supragastric belching that were associated 
more frequently with pathological acid exposure and esophageal hypomotility.  
Speech therapy has been proposed in a recent pilot study including 11 patients and resulted 
to be beneficial.
91
 Similar positive results have been reported with behavioral therapy in another 
study.
92
 Baclofen has also been applied with success in a small open label study.
93
 
 
Medical and surgical treatment in NERD, hypersensitive and functional heartburn 
Patients presenting with symptoms suggestive of reflux disease are often empirically treated 
with lifestyle advices and acid suppressive drugs, including PPIs.
94-97
 When patients do not respond 
to standard therapy, endoscopic and functional testing is performed to challenge the initial diagnosis 
and to investigate the reasons of treatment refractoriness. While the presence of erosive esophagitis 
confirms the diagnosis, a negative endoscopy cannot be used to rule out reflux disease, as a 
substantial part of GERD patients do not have no abnormalities seen on endoscopy (NERD).
98, 99
  
In most clinical trials, NERD patients are defined only by the presence of typical reflux symptoms 
and negative endoscopy. However, without appropriate functional testing it is difficult, if not 
impossible, to distinguish between FH, functional dyspepsia, and true NERD. Thus, the 
heterogeneity of the trial participants across studies could cause underestimation of the response 
rates to PPI treatment in NERD. Indeed, in a recent meta-analysis, Weijenborg et al. observed that 
in well-defined NERD patients (diagnosed by means of endoscopy and pathophysiological tests), 
the estimated complete symptom response rate after PPI therapy is comparable to the response rate 
in patients with ERD. In this paper the authors concluded that the previously reported low response 
rate in studies with patients classified as NERD was likely the result of inclusion of patients with 
upper gastrointestinal symptoms that did not have reflux disease.
100
  
Previously, Fass et al.
101
 observed a direct and strong correlation between acid exposure 
time and the positive response rate to omeprazole (40 mg in the morning and 20mg in the evening). 
Zerbib et al.
49
 described that patients with either positive symptom–reflux association 
analysis or AET>5% were more frequently associated with a positive response to PPI therapy. 
However,  the main finding of this study was that performing the multivariate analysis, the only 
factors associated with inadequate response to PPI were BMI ≤25 kg/m2 and the presence of 
functional dyspepsia or irritable bowel syndrome symptoms.
49
 Patel et al.
102
 observed that only 
acid-based reflux parameters (total AET and AET>4.0%) offer greater value over impedance-based 
nonacid-reflux parameters (total reflux events and bolus exposure time) in predicting symptomatic 
responses to PPI therapy.  
Controlling heartburn in patients with NERD can also be achieved with antacid or alginate 
compounds. Many clinical trials have demonstrated the benefit of these drugs, which continue to 
have a role in quickly relieving typical reflux symptoms in both NERD and erosive reflux 
disease.
103-109
 However, these over-the-counter drugs need multiple doses during the day, because 
of their short duration of action. Sodium alginate is a polysaccharide derived from seaweed. It binds 
water to form a viscous gum that floats in the proximal stomach, thereby reducing the acid 
pocket.
110
 Commercially available alginate preparations also contain an antacid. Sodium alginate 
might have the theoretical advantage of blocking both acid and WAR on the basis of the mechanical 
formation of a raft floating above gastric secretions, but its effect on the latter kind of reflux was not 
confirmed in a study using MII–pH testing.111 
As above mentioned, most reflux episodes happen during TLESRs, and these can be 
inhibited pharmacologically. The γ-aminobutyric acid (GABA)B-receptor agonist baclofen reduces 
the incidence of TLESRs and reflux episodes. Vela et al.
112
 have shown that baclofen induces a 
reduction of total amount of reflux events and contributes to improve the symptoms complained of 
by patients with reflux. On the other hand, this drug is not suitable for treatment of GERD because 
of its mainly neurologic central side-effects.
113 Unfortunately, the development of new drugs of this 
type with less severe adverse events than baclofen has been stopped, because of poor efficacy.
114
 
An additional therapeutic option might be surgery that should be considered for refractory 
patients with proven GERD and for those patients with weakly acidic reflux events.
16, 115, 116
 Five-
year results of a randomised European trial comparing maintenance PPI treatment (esomeprazole) 
with laparoscopic Nissen fundoplication
117
 showed that the remission rate did not differ between the 
two therapeutic strategies. However, at 5 years, acid regurgitation was more prevalent in the PPI 
group than in the fundoplication group. 
Several uncontrolled trials have shown that fundoplication is able to control symptoms 
related to both acid and WAR.
41, 118-120
 In particular, Broeders et al.
118
 have demonstrated that 
patients with normal AET and positive symptom association (HE patients) might benefit from 
fundoplication as well as patients with abnormal AET. Bredenoord et al.
121
 confirmed that 
fundoplication is able to reduce the abnormal levels of both chemical types of reflux.  Patel et al.
50
 
demonstrated in a large series of patients, after a 40-month follow-up period, that the response to 
laparoscopic anti-reflux therapy was consistent in patients selected by means of a MII-pH 
performed off-therapy. The authors showed that abnormal AET and the symptom-reflux association 
SAP consistently predicted symptomatic outcome in a multivariate analysis. 
Few data are available regarding characteristics of the refluxate, such as the presence of 
pepsin and bile acids that may contribute to symptom perception.
122
  In this review we focused that 
WAR events can cause not only regurgitation but also heartburn
5, 63
 and patients with symptomatic 
non-acid (weakly acidic) reflux on PPI treatment should be considered good candidates for anti-
reflux surgery. 
 
Conclusions 
Gastroesophageal reflux disease is a very common condition. Heartburn and regurgitation 
are the most representative and frequent symptoms. Reflux characteristics, other than acidity, such 
as the presence of WAR (including bile and pepsin) may also contribute to symptom perception. 
The cornerstone for treatment of GERD related symptoms is acid suppression with PPIs. In tertiary 
care center it is more frequent running into patients unresponsive to acid suppressive treatment. The 
lack of response to a sustained acid inhibition suggests that the GERD diagnosis is incorrect. 
Pathophysiological diagnosis of GERD should be performed preferably by means of combined pH-
impedance measurement. Patients should be recommended to accurately record symptoms to obtain 
the best information from symptom-reflux correlation scores. Up and coming parameters obtained 
from impedance and pH tracings as well as the presence of gas, aerophagia and supragastric 
belching should be considered, particularly when patients fail to record symptoms before 
considering functional diagnosis. Future studies are needed on these topics. 
When NERD patients have been well characterized, PPI treatment as well as antireflux 
surgery might be considered effective in them. It has been shown that a proportion of patients with 
reflux hypersensitivity can improve with antireflux surgery, especially if regurgitation is the main 
symptom and some structural disruption at the esophago-gastric junction may be documented.
123-125
 
At present functional upper GI symptoms are an exclusion criterion for antireflux surgery. 
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